News

Abbott has expanded XIENCE V USA post-approval study, designed to evaluate the safety and effectiveness of the company’s XIENCE V Everolimus Eluting Coronary Stent System in a real-world

Response Genetics has posted increase in total revenue by 4% to $1.9m for the second quarter, 2009, as compared to $1.8m for the same period last year. The

Astellas has announced that US Direct Court in Washington, DC has denied the Temporary Restraining Order and Preliminary Injunction, which have been requested by Astellas’ North American affiliate

Angiotech has received approval to market the Quill SRS Polydioxanone (PDO), Monoderm, Polypropylene and Nylon product lines in Brazil. The Quill SRS product lines include two absorbable sutures

Pacgen has completed the acquisition of Xphase Pharmaceuticals (Xphase), following the approval of the TSX Venture Exchange. Pursuant to a share purchase agreement with Xphase and its shareholders,

Amsterdam Molecular Therapeutics (AMT) has reported an increase in operating loss to E9.9m for the six months ended June 30, 2009, from E9.1m for the same period in

Oxygen has received approval to begin a phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte in traumatic brain injury (TBI). The company has named

King Pharmaceuticals (King) has received FDA approval for Embeda (morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use. Embeda, a long-acting opioid that is designed to

FDA has released its official and final report regarding the agency’s review of allegations made in a July newspaper article concerning mylan’s Morgantown, W.Va., manufacturing facility. The newspaper